Inhibition of early preneoplastic events in the rat liver by the somatostatin analog lanreotide

Cancer Science

Volumn 98, Issue 12, 2007, Pages 1831-1839

  Borbath, Ivan ^a   Leclercq, Isabelle A ^a   Abarca Quinones, Jorge ^a   Desaeger, Christine ^a   Lebrun, Valérie ^a   Moulin, Pierre ^a   Sempoux, Christine ^a   Horsmans, Yves ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DIETHYLNITROSAMINE; N (2 FLUORENYL)ACETAMIDE; SOMATOSTATIN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CANCER SIZE; CONTROLLED STUDY; DRUG MECHANISM; EARLY CANCER; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER CELL CARCINOMA; MALE; NONHUMAN; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL DIVISION; DIETHYLNITROSAMINE; LIVER NEOPLASMS; MALE; PEPTIDES, CYCLIC; POLYMERASE CHAIN REACTION; PRECANCEROUS CONDITIONS; RATS; RATS, WISTAR; RNA, NEOPLASM; SOMATOSTATIN;

EID: 35548964579     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00626.x     Document Type: Article

References (50)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-6.
2. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-50.
3. Williams GM. The significance of chemically-induced hepatocellular altered foci in rat liver and application to carcinogen detection. Toxicol Pathol 1989; 17: 663-72; discussion 673-4.
4. Altmann HW. Hepatic neoformations. Pathol Res Pract 1994; 190: 513-77.
5. Goldsworthy TL, Hanigan MH, Pitot HC. Models of hepatocarcinogenesis in the rat - contrasts and comparisons. Crit Rev Toxicol 1986; 17: 61-89.
6. Solt D, Farber E. New principle for analysis of chemical carcinogenesis. Nature 1976; 263: 701-3.
7. Becker RA, Shank RC. Kinetics of formation and persistence of ethylguanines in DNA of rats and hamsters treated with diethylnitrosamine. Cancer Res 1985; 45: 2076-84.
8. Lee JS, Chu IS, Mikaelyan A et al. Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet 2004; 36: 1306-11.
9. Dragan YP, Hully J, Crow R, Mass M, Pitot HC. Incorporation of bromodeoxyuridine in glutathione S-transferase-positive hepatocytes during rat multistage hepatocarcinogenesis. Carcinogenesis 1994; 15: 1939-47.
10. Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 2006; 17: 1733-42.
11. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001; 28: 836-46.
12. Reynaert H, Rombouts K, Vandermonde A et al. Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma. Gut 2004; 53: 1180-9.
13. Reubi JC, Zimmermann A, Jonas S et al. Regulatory peptide receptors in human hepatocellular carcinomas. Gut 1999; 45: 766-74.
14. Blaker M, Schmitz M, Gocht A et al. Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas. J Hepatol 2004; 41: 112-8.
15. Reynaert H, Vaeyens F, Qin H et al. Somatostatin suppresses endothelin-1-induced rat hepatic stellate cell contraction via somatostatin receptor subtype 1. Gastroenterology 2001; 121: 915-30.
16. Yamada Y, Post SR, Wang K, Tager HS, Bell GI, Seino S. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Natl Acad Sci USA 1992; 89: 251-5.
17. Jia WD, Xu GL, Xu RN et al. Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts. J Cancer Res Clin Oncol 2003; 129: 327-34.
18. Chen X, Liu Z, Ai Z. Antineoplastic mechanism of Octreotide action in human hepatoma. Chin Med J (Engl) 2001; 114: 1167-70.
19. Liu HL, Huo L, Wang L. Octreotide inhibits proliferation and induces apoptosis of hepatocellular carcinoma cells. Acta Pharmacol Sin 2004; 25: 1380-6.
20. Notas G, Kolios G, Mastrodimou N et al. Cortistatin production by HepG2 human hepatocellular carcinoma cell line and distribution of somatostatin receptors. J Hepatol 2004; 40: 792-8.
21. Raderer M, Hejna MH, Muller C et al. Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo. Int J Oncol 2000; 16: 1197-201.
22. Schindel DT, Grosfeld JL. Hepatic resection enhances growth of residual intrahepatic and subcutaneous hepatoma, which is inhibited by octreotide. J Pediatr Surg 1997; 32: 995-7; discussion 997-8.
23. Barbare JC, Bouche O, Bonnetain F, Lombard-Bohas C et al., Fédération Francophone de Cancérologie Digestive. Treatment of advanced hepatocellular carcinoma with long-acting octreotide: Preliminary results of a randomized placebo-controlled trial (FFCD-ANGH 2001-01 CHOC). J Clin Oncol 2005; 23 (Sup pl): 4036.
24. Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos ON. Treatment of hepatocellular carcinoma with octreotide: A randomised controlled study. Gut 1998; 42: 442-7.
25. Yuen MF, Poon RT, Lai CL et al. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 2002; 36: 687-91.
26. Cebon J. Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. Br J Cancer2006; 95: 853-61.
27. Becker G, Allgaier HP, Olschewski M, Zahringer A, Blum HE, HECTOR Study Group. Long-acting octreotide versus placebo for treatment of advanced HCC: A randomized controlled double-blind study. Hepatology 2007; 45: 9-15.
28. Imai T, Masui T, Ichinose M et al. Reduction of glutathione S-transferase P-form mRNA expression in remodeling nodules in rat liver revealed by in situ hybridization. Carcinogenesis 1997; 18: 545-51.
29. Charland S, Boucher MJ, Houde M, Rivard N. Somatostatin inhibits Akt phosphorylation and cell cycle entry, but not p42/p44 mitogen-activated protein (MAP) kinase activation in normal and tumoral pancreatic acinar cells. Endocrinology 2001; 142: 121-8.
30. de Lujan Alvarez M, Cerliani JP, Monti J et al. The in vivo apoptotic effect of interferon alfa-2b on rat preneoplastic liver involves Bax protein. Hepatology 2002; 35: 824-33.
31. Xu YH, Pitot HC. An improved stereologic method for three-dimensional estimation of particle size distribution from observations in two dimensions and its application. Comput Methods Programs Biomed 2003; 72: 1-20.
32. Duan WR, Garner DS, Williams SD, Funckes-Shippy CL, Spath IS, Blomme EA. Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts. J Pathol 2003; 199: 221-8.
33. Starkel P, Bishop K, Horsmans Y, Strain AJ. Expression and DNA-binding activity of signal transducer and activator of transcription 3 in alcoholic cirrhosis compared to normal liver and primary biliary cirrhosis in humans. Am J Pathol 2003; 162: 587-96.
34. Camma C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: An evidence-based approach. J Hepatol 2001; 34: 593-602.
35. Ikeda K, Arase Y, Saitoh S et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumorA prospective randomized study of hepatitis C-related liver cancer. Hepatology 2000; 32: 228-32.
36. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 2002; 89: 418-22.
37. Suou T, Mitsuda A, Koda M et al. Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: A pilot study. Hepatol Res 2001; 20: 301-11.
38. Muto Y, Moriwaki H, Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 1999; 340: 1046-7.
39. Nakaji M, Yano Y, Ninomiya T et al. IFN-alpha prevents the growth of pre-neoplastic lesions and inhibits the development of hepatocellular carcinoma in the rat. Carcinogenesis 2004; 25: 389-97.
40. Sakakima Y, Hayakawa A, Nagasaka T, Nakao A. Prevention of hepatocarcinogenesis with phosphatidylcholine and menaquinone-4. In vitro and in vivo experiments. J Hepatol 2007; 47: 83-92.
41. Pitot HC. Altered hepatic foci: Their role in murine hepatocarcinogenesis. Annu Rev Pharmacol Toxicol 1990; 30: 465-500.
42. Dragan YP, Campbell HA, Baker K, Vaughan J, Mass M, Pitot HC. Focal and non-focal hepatic expression of placental glutathione S-transferase in carcinogen-treated rats. Carcinogenesis 1994; 15: 2587-91.
43. Tatematsu M, Aoki T, Kagawa M, Mera Y, Ito N. Reciprocal relationship between development of glutathione S-transferase positive liver foci and proliferation of surrounding hepatocytes in rats. Carcinogenesis 1988; 9: 221-5.
44. Verna L, Whysner J, Williams GM. 2-Acetylaminofluorene mechanistic data and risk assessment: DNA reactivity, enhanced cell proliferation and tumor initiation. Pharmacol Ther 1996; 71: 83-105.
45. Rasmussen E, Eriksson B, Oberg K, Bondesson U, Rane A. Selective effects of somatostatin analogs on human drug-metabolizing enzymes. Clin Pharmacol Ther 1998; 64: 150-9.
46. Blanck A, Hansson T, Eriksson LC, Gustafsson JA. Growth hormone modifies the growth rate of enzyme-altered hepatic foci in male rats treated according to the resistant hepatocyte model. Carcinogenesis 1987; 8: 1585-8.
47. Pages P, Benali N, Saint-Laurent N et al. sst2 somatostatin receptor mediates cell cycle arrest and induction of p27 (Kip1). Evidence for the role of SHP-1. J Biol Chem 1999; 274: 15186-93.
48. Kwon YH, Jovanovic A, Serfas MS, Kiyokawa H, Tyner AL. P21 functions to maintain quiescence of p27-deficient hepatocytes. J Biol Chem 2002; 277: 41417-22.
49. Lennartsson P, Hogberg J, Stenius U. Wild-type p53 expression in liver tissue and in enzyme-altered foci: An in vivo investigation on diethylnitrosamine-treated rats. Carcinogenesis 1998; 19: 1231-7.
50. Hsu SL, Chen MC, Chou YH, Hwang GY, Yin SC. Induction of p21 (CIP1/Waf1) and activation of p34 (cdc2) involved in retinoic acid-induced apoptosis in human hepatoma Hep3B cells. Exp Cell Res 1999; 248: 87-96.